Wyeth Pharmaceuticals expands facility
Growing demand for a vaccine that protects babies and young children from diseases such as pneumococcal meningitis, has prompted the
Growing demand for a vaccine that protects babies and young children from diseases such as pneumococcal meningitis, has prompted the £3.25m expansion of facilities at Wyeth Pharmaceuticals.
Growing demand for a vaccine that protects babies and young children from diseases such as pneumococcal meningitis, has prompted the £3.25m expansion of facilities at Wyeth Pharmaceuticals.
The research-driven pharmaceutical company is to install a second packaging line at to produce its Prevenar vaccines.
The move will enable the site in Havant to boost the number of vaccines packaged and distributed to a projected 22 million this year from just 10 million in 2005.
Since September last year, Prevenar has been part of the UK's routine childhood immunisation programme. The facility also exports the vaccine to European, Latin American, and Asia Pacific markets, for immunisation programmes in countries such as France, Germany, Spain, Holland and Australia.
Plant director Dr Jim Neville, said: "At Havant, we have a key role within Wyeth's global operations as a highly specialised facility, managing the packaging and distribution of some of the Company's most advanced medicines and vaccines," he added.
The Havant site is also responsible for packaging and distributing Meningitec - a vaccine against meningitis C.